Dr. Inge Bronckers of Radboud University and collaborators in PeDRA’s Psoriasis Investigators Group (PsIG) recently published results of their study comparing the use of methotrexate to biologics for the treatment of moderate-to-severe psoriasis in children. First available on-line in JAMA Dermatology on February 5, 2020, the publication titled “A Comparison of Psoriasis Severity in Pediatric Patients Treated With Methotrexate vs Biologic Agents,” presents the conclusion that both methotrexate and biologics improve symptoms of pediatric psoriasis, with biologics being associated with a greater level of improvement. The study analyzed retrospective data from 20 collaborating sites across Europe and North America.
This publication represents the third publication from the PsIG since 2017 and the second from Dr. Bronckers.
Learn more about these and other papers published by PeDRA’s working groups, on the PeDRA Publication Page.